Clarity Pharmaceuticals Ltd

ASX:CU6 Stock Report

Market Cap: AU$797.0m

Clarity Pharmaceuticals Management

Management criteria checks 3/4

Clarity Pharmaceuticals' CEO is Colin Biggin, appointed in Oct 2019, has a tenure of 4.5 years. total yearly compensation is A$929.70K, comprised of 47.8% salary and 52.2% bonuses, including company stock and options. directly owns 0.59% of the company’s shares, worth A$4.68M. The average tenure of the management team and the board of directors is 3.3 years and 4.3 years respectively.

Key information

Colin Biggin

Chief executive officer

AU$929.7k

Total compensation

CEO salary percentage47.8%
CEO tenure4.5yrs
CEO ownership0.6%
Management average tenure3.3yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Jan 03
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

May 29
We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Aug 24
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Jan 13
Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

CEO Compensation Analysis

How has Colin Biggin's remuneration changed compared to Clarity Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-AU$31m

Sep 30 2023n/an/a

-AU$28m

Jun 30 2023AU$930kAU$444k

-AU$25m

Mar 31 2023n/an/a

-AU$23m

Dec 31 2022n/an/a

-AU$21m

Sep 30 2022n/an/a

-AU$23m

Jun 30 2022AU$811kAU$347k

-AU$24m

Mar 31 2022n/an/a

-AU$21m

Dec 31 2021n/an/a

-AU$19m

Sep 30 2021n/an/a

-AU$15m

Jun 30 2021AU$907kAU$308k

-AU$10m

Mar 31 2021n/an/a

-AU$9m

Dec 31 2020n/an/a

-AU$9m

Sep 30 2020n/an/a

-AU$8m

Jun 30 2020AU$657kAU$303k

-AU$7m

Compensation vs Market: Colin's total compensation ($USD604.92K) is about average for companies of similar size in the Australian market ($USD775.51K).

Compensation vs Earnings: Colin's compensation has increased whilst the company is unprofitable.

CEO

Colin Biggin

4.5yrs

Tenure

AU$929,701

Compensation

Dr. Colin David Biggin, Ph D., has been Managing Director, Chief Executive Officer and Executive Director at Clarity Pharmaceuticals Ltd since October 1, 2019. Dr. Biggin joined Clarity Pharmaceuticals Pty...

Leadership Team

NamePositionTenureCompensationOwnership
Alan Taylor
Executive Chairman10.4yrsAU$1.13m4.59%
A$ 36.6m
Colin Biggin
MD, CEO & Executive Director4.5yrsAU$929.70k0.59%
A$ 4.7m
David Green
Chief Financial Officer2yrsAU$265.49kno data
Shaemus Gleason
Executive Vice President of Operationsno datano datano data
Matthew Harris
CTO & Director of Technologyno dataAU$241.43k1.98%
A$ 15.8m
Jeffrey Norenberg
Chief Scientific Officer1.6yrsno datano data
Michelle Parker
Executive Vice President of Global Clinical Operationsno datano datano data
Robert Vickery
Company Secretaryno dataAU$268.69kno data

3.3yrs

Average Tenure

Experienced Management: CU6's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alan Taylor
Executive Chairman10.4yrsAU$1.13m4.59%
A$ 36.6m
Colin Biggin
MD, CEO & Executive Director4.5yrsAU$929.70k0.59%
A$ 4.7m
Christopher Roberts
Non-Executive Director8.1yrsAU$81.75k5.84%
A$ 46.6m
Thomas Ramdahl
Non-Executive Director5.1yrsAU$81.75k0.17%
A$ 1.4m
Robert Thomas
Lead Independent Director2.7yrsAU$79.56k0.37%
A$ 2.9m
Neal Shore
Member of Scientific Advisory Board1.9yrsno datano data
Rosanne Robinson
Independent Non-Executive Director13.5yrsAU$90.59kno data
Jason Lewis
Member of Scientific Advisory Boardno datano datano data
Oliver Sartor
Member of Scientific Advisory Board4.1yrsno datano data
Paul Donnelly
Member of Scientific Advisory Boardno datano datano data
Andrei Iagaru
Member of Scientific Advisory Board2yrsno datano data
Louise Emmett
Member of Scientific Advisory Board1.8yrsno datano data

4.3yrs

Average Tenure

69yo

Average Age

Experienced Board: CU6's board of directors are considered experienced (4.3 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.